NKGen Biotech targets moderate-stage Alzheimer’s disease with immunotherapy that enhances the body’s natural ability to destroy diseased cells.
Clinical-stage biotechnology company NKGen Biotech has received Fast Track designation from the US FDA for its natural killer (NK) cell therapeutic targeting moderate Alzheimer’s disease. The drug, called troculeucel, is an ex vivo expanded autologous cell therapy designed to harness the natural ability of NK cells to eliminate diseased cells and enhance immune response.
Based in Santa Ana, California, NKGen specializes in the development and commercialization of autologous and allogeneic NK cell therapeutics. NK cells are a crucial part of the immune system, responsible for identifying and destroying abnormal or diseased cells while preserving healthy ones. Their function extends beyond immune defense to include protection of the central nervous system, including the brain. However, NK cell activity can decline due to factors such as aging, stress, infections, certain medications, and sleep disorders. This decline has been associated with the progression of neurodegenerative diseases like Alzheimer’s.
According to NKGen, moderate-stage Alzheimer’s represents approximately 30% of all Alzheimer’s cases. While much of the current research and development effort has focused on early or mild-stage disease, moderate-stage patients have limited treatment options.
The FDA’s decision to grant troculeucel Fast Track designation follows promising results from a Phase 1 trial that demonstrated early indications of clinical benefit and a favorable safety profile. Unlike genetically modified cell therapies such as CAR-T, NKGen says its autologous therapies are derived from a patient’s own blood, reducing the likelihood of side effects.
The designation is designed to expedite the drug’s path to market by increasing engagement with the FDA and potentially allows for accelerated approval and priority review of regulatory submissions.
“This decision underscores the significant unmet need for effective treatments for patients with moderate AD,” said NKGen CEO Dr Paul Y Song. “Receiving Fast Track designation will significantly accelerate the drug development process, bringing us one step closer to delivering this promising therapy to AD patients in need, and ensuring faster access to a potentially life-changing treatment.”
NKGen now aims to accelerate the clinical development of troculeucel, and is currently enrolling participants in a Phase 2a trial, with plans to share clinical data by the end of 2025.
